Vol. 1 No. 9 (2021)
Reimbursement Recommendations

Elexacaftor-Tezacaftor-Ivacaftor and Ivacaftor (Trikafta)

Published September 16, 2021

Key Messages

  • CADTH recommends that Trikafta be reimbursed by public drug plans for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who have at least 1 F508del mutation in the CFTR gene if certain conditions are met.

  • Trikafta should be reimbursed for patients who have a percent predicted forced expiratory volume in 1 second (ppFEV1) of 90% or less at the onset of Trikafta treatment.

  • At least 1 of the following must be demonstrated after 6 months of treatment with Trikafta: an increase of at least 5% in ppFEV1, a decrease in the number of pulmonary exacerbations or number of days that antibiotics needed to be taken for pulmonary exacerbations, a decrease in CF-related hospitalizations, no decline in BMI, or an improvement of at least 4 points in the CFQ-R respiratory domain scale. The price of Trikafta must be lowered to be cost-effective and affordable.